FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Antimicrob Agents Chemother / Pharmacokinetics of acyclovir after intravenous infusion of ...
Antimicrobial agents and chemotherapy2007; 51(12); 4308-4314; doi: 10.1128/AAC.00116-07

Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.

Abstract: The purpose of this study was twofold. The first aim was to evaluate the oral bioavailability and pharmacokinetics (PKs) of acyclovir in horses after intravenous (i.v.) administration and after oral administration of acyclovir and its prodrug, valacyclovir. Second, we aimed to combine these PK data with pharmacodynamic (PD) information, i.e., 50% effective concentrations (EC(50) values) from in vitro studies, to design an optimal dosage schedule. Three treatments were administered to healthy adult horses: 10 mg of acyclovir/kg of body weight delivered as an i.v. infusion over 1 h, 20 mg of acyclovir/kg administered as tablets by nasogastric intubation, and 20 mg of valacyclovir/kg administered as tablets by nasogastric intubation. Total plasma concentrations were measured by a high-performance liquid chromatography method combined with fluorescence detection, while unbound plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. The peak concentration of i.v. acyclovir was approximately 10 mug/ml for both the total and the unbound plasma concentrations. The mean half-life of elimination was between 5.05 h (total concentration) and 11.9 h (unbound concentration). Oral administration of acyclovir resulted in low maximum concentration in plasma (C(max)) and poor bioavailability. A 10-times-higher C(max) and an 8-times-higher bioavailability were achieved with oral administration of valacyclovir. The i.v. administration of 10 mg/kg acyclovir and the oral administration of 20 mg/kg valacyclovir achieved concentrations within the sensitivity range of equine herpesvirus type 1 (EHV-1). The higher bioavailability of valacyclovir makes it an attractive candidate for the prophylactic and/or therapeutic treatment of horses infected with EHV-1. The results from the PK/PD modeling showed that a dosage of 40 mg/kg valacyclovir, administered three times daily, would be sufficient to reach plasma concentrations above the EC(50) values.
Get Full Text
Publication Date: 2007-09-10 PubMed ID: 17846132PubMed Central: PMC2167972DOI: 10.1128/AAC.00116-07Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study explores how the body absorbs and processes the drug acyclovir, administered orally and intravenously, and its prodrug valacyclovir in horses. The findings could be instrumental in designing an optimal dosage schedule for treating horses infected with equine herpesvirus.

Purpose and Design of Study

  • This research aimed to understand how well acyclovir, an antiviral medication, is absorbed and processed (pharmacokinetics) when given orally and intravenously to horses. This was also compared to the administration of its prodrug valacyclovir, which is a medicine that converts into acyclovir once inside the body.
  • Additionally, the researchers sought to use this pharmacokinetic data in conjunction with pharmacodynamic information, which is how the drug influences the body, to construct an effective dosage plan. The pharmacodynamic information used in this case were the 50% effective concentrations (EC50 values) from laboratory studies.

Methodology

  • The experiment was conducted on healthy adult horses with three different treatments: intravenous acyclovir, oral acyclovir, and oral valacyclovir. All three were given considering the horse’s body weight.
  • The study used high-performance liquid chromatography and fluorescence detection to measure the amount of the drug in plasma. Moreover, liquid chromatography-tandem mass spectrometry was used to determine the unbound plasma concentrations of the drug.

Key Findings

  • The study found that the peak concentration of acyclovir given intravenously was roughly the same for both the total and the unbound plasma concentrations. The average elimination half-life (time taken for the concentration of the drug to reduce by half in the body) ranged between 5.05 hours (total concentration) and 11.9 hours (unbound concentration).
  • The oral administration of acyclovir resulted in a low peak concentration in plasma (Cmax) and poor bioavailability (the portion of the drug that enters circulation when introduced into the body).
  • Conversely, valacyclovir administrated orally resulted in a ten times higher plasma peak concentration and an eight times better bioavailability than oral administration of acyclovir.
  • The study shows that intravenous acyclovir (at 10 mg/kg) and oral valacyclovir (at 20 mg/kg) reach concentrations within the sensitivity range of equine herpesvirus type 1 (EHV-1), a leading cause of viral disease in horses.

Implication and Future Directions

  • The study concludes that due to its higher bioavailability, valacyclovir is a better candidate for prevention and treatment in horses afflicted with EHV-1 compared to acyclovir.
  • The paper proposes that a dosage of 40 mg/kg valacyclovir, administered three times daily, should be enough to achieve plasma concentrations above the EC50 values.
  • This research could help in creating a better treatment regimen for horse-owners and veterinary hospitals, improving the health and wellbeing of the animals suffering from EHV-1.

Cite This Article

APA
Garré B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, Nauwynck H, Deprez P, De Backer P, Croubels S. (2007). Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother, 51(12), 4308-4314. https://doi.org/10.1128/AAC.00116-07

Publication

Antimicrobial agents and chemotherapy
ISSN: 0066-4804
NlmUniqueID: 0315061
Country: United States
Language: English
Volume: 51
Issue: 12
Pages: 4308-4314

Researcher Affiliations

Garré, B
  • Department of Pharmacology, Toxicology, Biochemistry, and Organ Physiology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Shebany, K
    Gryspeerdt, A
      Baert, K
        van der Meulen, K
          Nauwynck, H
            Deprez, P
              De Backer, P
                Croubels, S

                  MeSH Terms

                  • Acyclovir / administration & dosage
                  • Acyclovir / analogs & derivatives
                  • Acyclovir / blood
                  • Acyclovir / pharmacokinetics
                  • Administration, Oral
                  • Algorithms
                  • Animals
                  • Antiviral Agents / administration & dosage
                  • Antiviral Agents / pharmacokinetics
                  • Chromatography, High Pressure Liquid / methods
                  • Horses
                  • Infusions, Intravenous
                  • Metabolic Clearance Rate
                  • Prodrugs / administration & dosage
                  • Prodrugs / pharmacokinetics
                  • Tandem Mass Spectrometry
                  • Valacyclovir
                  • Valine / administration & dosage
                  • Valine / analogs & derivatives
                  • Valine / pharmacokinetics

                  References

                  This article includes 31 references
                  1. Allen GP, Bryans JT. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.. Prog Vet Microbiol Immunol 1986;2:78-144.
                    pubmed: 2856183
                  2. Anonymous. Antiviral agents. 13th ed., p. 536-563.
                  3. Anonymous. Commission Decision (2002/657/EC) of 17 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Official European Communication No. L221, p. 8.
                  4. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy.. J Antimicrob Chemother 2003 Dec;52(6):893-8.
                    pubmed: 14613960doi: 10.1093/jac/dkg482google scholar: lookup
                  5. Bentz BG, Maxwell LK, Erkert RS, Royer CM, Davis MS, MacAllister CG, Clarke CR. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses.. J Vet Intern Med 2006 May-Jun;20(3):589-94.
                    pubmed: 16734094doi: 10.1892/0891-6640(2006)20[589:poaasi]2.0.co;2google scholar: lookup
                  6. Bryans JT, Allen GP. Herpesviral diseases of the horse. p. 176-229.
                  7. de Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP 3rd, Kirk LE, Page DA, Elion GB. Acyclovir kinetics after intravenous infusion.. Clin Pharmacol Ther 1979 Dec;26(6):718-28.
                    pubmed: 227639doi: 10.1002/cpt1979266718google scholar: lookup
                  8. Dorsky DI, Crumpacker CS. Drugs five years later: acyclovir.. Ann Intern Med 1987 Dec;107(6):859-74.
                    pubmed: 3318610doi: 10.7326/0003-4819-107-6-859google scholar: lookup
                  9. Fletcher C, Bean B. Evaluation of oral acyclovir therapy.. Drug Intell Clin Pharm 1985 Jul-Aug;19(7-8):518-24.
                    pubmed: 2992899doi: 10.1177/106002808501900703google scholar: lookup
                  10. Friday PA, Scarratt WK, Elvinger F, Timoney PJ, Bonda A. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses.. J Vet Intern Med 2000 Mar-Apr;14(2):197-201.
                    pubmed: 10772493doi: 10.1892/0891-6640(2000)014<0197:aapweh>2.3.co;2google scholar: lookup
                  11. Gabrielsson JL, Weiner DL. Methodology for pharmacokinetic/pharmacodynamic data analysis.. Pharm Sci Technol Today 1999 Jun;2(6):244-252.
                    pubmed: 10366840doi: 10.1016/s1461-5347(99)00162-5google scholar: lookup
                  12. Garré B, van der Meulen K, Nugent J, Neyts J, Croubels S, De Backer P, Nauwynck H. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet.. Vet Microbiol 2007 May 16;122(1-2):43-51.
                    pubmed: 17276631doi: 10.1016/j.vetmic.2007.01.004google scholar: lookup
                  13. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. rev. and expanded.
                  14. Henninger R. Epidemic neurological disease due to equine herpesvirus 1: the University of Findlay English Equestrian Center. p. 621-624.
                  15. Krasny HC, de Miranda P, Blum MR, Elion GB. Pharmacokinetics and bioavailability of acyclovir in the dog.. J Pharmacol Exp Ther 1981 Feb;216(2):281-8.
                    pubmed: 7463350
                  16. MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir.. J Antimicrob Chemother 2004 Jun;53(6):899-901.
                    pubmed: 15140857doi: 10.1093/jac/dkh244google scholar: lookup
                  17. McCartan CG, Russell MM, Wood JL, Mumford JA. Clinical, serological and virological characteristics of an outbreak of paresis and neonatal foal disease due to equine herpesvirus-1 on a stud farm.. Vet Rec 1995 Jan 7;136(1):7-12.
                    pubmed: 7900264doi: 10.1136/vr.136.1.7google scholar: lookup
                  18. Meadows KC, Dressman JB. Mechanism of acyclovir uptake in rat jejunum.. Pharm Res 1990 Mar;7(3):299-303.
                    pubmed: 2339106doi: 10.1023/a:1015890516119google scholar: lookup
                  19. Murray MJ, del Piero F, Jeffrey SC, Davis MS, Furr MO, Dubovi EJ, Mayo JA. Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm.. J Vet Intern Med 1998 Jan-Feb;12(1):36-41.
                    pubmed: 9503358doi: 10.1111/j.1939-1676.1998.tb00494.xgoogle scholar: lookup
                  20. Ormrod D, Goa K. Valaciclovir: a review of its use in the management of herpes zoster.. Drugs 2000 Jun;59(6):1317-40.
                    pubmed: 10882165doi: 10.2165/00003495-200059060-00009google scholar: lookup
                  21. Ostlund EN. The equine herpesviruses.. Vet Clin North Am Equine Pract 1993 Aug;9(2):283-94.
                    pubmed: 8395324doi: 10.1016/s0749-0739(17)30396-6google scholar: lookup
                  22. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.. Drugs 1996 Nov;52(5):754-72.
                    pubmed: 9118821doi: 10.2165/00003495-199652050-00009google scholar: lookup
                  23. Slater JD, Lunn DP, Horohov DW, Antczak DF, Babiuk L, Breathnach C, Chang YW, Davis-Poynter N, Edington N, Ellis S, Foote C, Goehring L, Kohn CW, Kydd J, Matsumura T, Minke J, Morley P, Mumford J, Neubauer T, O'Callaghan D, Osterrieder K, Reed S, Smith K, Townsend H, van der Meulen K, Whalley M, Wilson WD. Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004.. Vet Immunol Immunopathol 2006 May 15;111(1-2):3-13.
                    pubmed: 16542736doi: 10.1016/j.vetimm.2006.01.004google scholar: lookup
                  24. Stierstorfer B, Eichhorn W, Schmahl W, Brandmüller C, Kaaden OR, Neubauer A. Equine herpesvirus type 1 (EHV-1) myeloencephalopathy: a case report.. J Vet Med B Infect Dis Vet Public Health 2002 Feb;49(1):37-41.
                    pubmed: 11911591doi: 10.1046/j.1439-0450.2002.00537.xgoogle scholar: lookup
                  25. Tanna S, Wood C, Lawrence MJ. Competition studies to elucidate the mechanisms of acyclovir uptake in the small intestine. J. Pharm. Pharmacol. 44(Suppl. 1):1047.
                  26. Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.. Antimicrob Agents Chemother 2001 Jan;45(1):150-7.
                    pmc: PMC90253pubmed: 11120958doi: 10.1128/aac.45.1.150-157.2001google scholar: lookup
                  27. van der Meulen KM, Vercauteren G, Nauwynck HJ, Pensaert MB. A local epidemic of equine herpesvirus 1-induced neurological disorders in Belgium. Flem. Vet. J. 72:366-372.
                  28. van Maanen C, Sloet van Oldruitenborgh-Oosterbaan MM, Damen EA, Derksen AG. Neurological disease associated with EHV-1-infection in a riding school: clinical and virological characteristics.. Equine Vet J 2001 Mar;33(2):191-6.
                    pubmed: 11266070doi: 10.1111/j.2042-3306.2001.tb00600.xgoogle scholar: lookup
                  29. Wilkins PA. Acyclovir in the treatment of EHV-1 myeloencephalopathy. p. 170-172.
                  30. Wilkins PA, Papich M, Sweeney RW. Pharmacokinetics of acyclovir in adult horses. J. Vet. Emergency Crit. Care 15:174-178.
                  31. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.. J Pharmacokinet Biopharm 1978 Apr;6(2):165-75.
                    pubmed: 671222doi: 10.1007/bf01117450google scholar: lookup

                  Citations

                  This article has been cited 12 times.
                  1. Wang YC, Juan SH, Li CH, Chou CL, Chen LY, Chien LN, Fang TC. Valacyclovir-associated neurotoxicity among patients on hemodialysis and peritoneal dialysis: A nationwide population-based study.. Front Med (Lausanne) 2022;9:997379.
                    doi: 10.3389/fmed.2022.997379pubmed: 36203771google scholar: lookup
                  2. Khammesri S, Ampasavate C, Hongwiset D, Mektrirat R, Sangsrijan S, Brown JL, Thitaram C. Pharmacokinetics and analytical determination of acyclovir in Asian elephant calves (Elephas maximus).. Vet Anim Sci 2022 Mar;15:100227.
                    doi: 10.1016/j.vas.2021.100227pubmed: 35024493google scholar: lookup
                  3. Sumabe BK, Ræder SB, Røst LM, Sharma A, Donkor ES, Mosi L, Duodu S, Bruheim P, Otterlei M. Nucleoside Analogues Are Potent Inducers of Pol V-mediated Mutagenesis.. Biomolecules 2021 Jun 5;11(6).
                    doi: 10.3390/biom11060843pubmed: 34198819google scholar: lookup
                  4. Khammesri S, Mathura Y, Boonprasert K, Ampasavate C, Hongwiset D, Brown JL, Thitaram C. Successful treatment of elephant endotheliotropic herpesvirus infection in an Asian elephant (Elephas maximus) calf by oral acyclovir medication: Case report.. J Vet Med Sci 2021 Jan 14;83(1):125-129.
                    doi: 10.1292/jvms.20-0375pubmed: 33239478google scholar: lookup
                  5. Costa T, Ribeiro A, Machado R, Ribeiro C, Lanceros-Mendez S, Cavaco-Paulo A, Almeida A, das Neves J, Lúcio M, Viseu T. Polymeric Electrospun Fibrous Dressings for Topical Co-delivery of Acyclovir and Omega-3 Fatty Acids.. Front Bioeng Biotechnol 2019;7:390.
                    doi: 10.3389/fbioe.2019.00390pubmed: 31850337google scholar: lookup
                  6. Easton-Jones CA, Madigan JE, Barnum S, Maxwell LK, Taylor SD, Arnesen T, Pusterla N. Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis.. J Vet Intern Med 2018 Sep;32(5):1763-1767.
                    doi: 10.1111/jvim.15230pubmed: 30221792google scholar: lookup
                  7. Maxwell LK, Bentz BG, Gilliam LL, Ritchey JW, Pusterla N, Eberle R, Holbrook TC, McFarlane D, Rezabek GB, Meinkoth J, Whitfield C, Goad CL, Allen GP. Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses.. Am J Vet Res 2017 Oct;78(10):1126-1139.
                    doi: 10.2460/ajvr.78.10.1126pubmed: 28945127google scholar: lookup
                  8. Toishi Y, Tsunoda N, Kirisawa R. Occurrence of equine coital exanthema (ECE) in stallions in Japan and effectiveness of treatment with valacyclovir for ECE.. J Vet Med Sci 2017 Mar 23;79(3):632-635.
                    doi: 10.1292/jvms.16-0511pubmed: 28123140google scholar: lookup
                  9. Carmichael RJ, Whitfield C, Maxwell LK. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.. J Vet Pharmacol Ther 2013 Oct;36(5):441-9.
                    doi: 10.1111/jvp.12029pubmed: 23301502google scholar: lookup
                  10. Baum MM, Butkyavichene I, Gilman J, Kennedy S, Kopin E, Malone AM, Nguyen C, Smith TJ, Friend DR, Clark MR, Moss JA. An intravaginal ring for the simultaneous delivery of multiple drugs.. J Pharm Sci 2012 Aug;101(8):2833-43.
                    doi: 10.1002/jps.23208pubmed: 22619076google scholar: lookup
                  11. Fulton A, Peters ST, Perkins GA, Jarosinski KW, Damiani A, Brosnahan M, Buckles EL, Osterrieder N, Van de Walle GR. Effective treatment of respiratory alphaherpesvirus infection using RNA interference.. PLoS One 2009;4(1):e4118.
                    doi: 10.1371/journal.pone.0004118pubmed: 19122813google scholar: lookup
                  12. Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement.. Pharm Res 2009 May;26(5):1261-9.
                    doi: 10.1007/s11095-008-9730-0pubmed: 18839288google scholar: lookup
                  Subscribe to our newsletter
                  Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.